PYC Therapeutics Ltd (ASX: PYC) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


PYC Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $559.93 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 4.67 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return 10.39%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • PYC Therapeutics Ltd (ASX: PYC)
    Latest News

    a man in a business suit sits at his laptop computer at his desk and smiles broadly in an office setting, giving an air of optimism and confidence.
    Share Gainers

    Why these three ASX All Ords stocks are leading the charge higher this week

    These three ASX All Ords shares rocketed higher this week. But how?

    Read more »

    Woman looks amazed and shocked as she looks at her laptop.
    Share Gainers

    Why IDP Education, Novonix, PYC, and Regis Resources share are racing higher

    These shares are ending the week strongly. Here's what you need to know.

    Read more »

    a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
    Small Cap Shares

    2 ASX penny stocks to consider buying while their prices are this cheap

    Analysts think high rewards could be on offer from these high risk stocks.

    Read more »

    Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
    Share Gainers

    Why Appen, Mayne Pharma, Playside, and PYC shares are storming higher

    These shares are ending the week on a positive note. But why?

    Read more »

    A man in a business suit whose face isn't shown hands over two australian hundred dollar notes from a pile of notes in his other hand to an outstretched hand of another person.
    Healthcare Shares

    Guess which ASX All Ords insider just bought 50 million shares in their company

    Some major insider buying has taken place. What does this mean?

    Read more »

    A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
    Share Fallers

    Why IDP Education, JB Hi-Fi, PYC, and Renascor shares are falling today

    These shares are missing out on the good times on Thursday. But why?

    Read more »

    A worried man holds his head and look at his computer.
    Share Fallers

    Why Arcadium Lithium, IAG, PYC Therapeutics, and Zip shares are falling today

    These ASX shares are starting the year in the red.

    Read more »

    A medical researcher works on a bichip, indicating share price movement in ASX tech companies
    Share Market News

    Why is the PYC Therapeutics share price up 170% in a year?

    The PYC Therapeutics share price has risen 170% this year and 13% this month, following promising results in the development…

    Read more »

    row of piggy banks with large one receiving injection representing rising Immutep share price
    Share Market News

    Why the PYC Therapeutics (ASX:PYC) share price is up 11% today

    The PYC Therapeutics share price is higher today after the company announced that it has added another drug to its…

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Share Market News

    Why the PYC Therapeutics (ASX:PYC) share price is up 9% today

    The PYC Therapeutics share price is up 9% today following a promising ASX announcement on the effectiveness of its lead…

    Read more »

    a woman
    ⏸️ Investing

    Why Phylogica Limited soared 80% today

    Phylogica Limited (ASX:PYC) reports some excellent news

    Read more »

    PYC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About PYC Therapeutics Ltd

    PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principalbusiness activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

    PYC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    16 Jul 2024 $0.12 $-0.01 -7.69% 1,538,532 $0.13 $0.13 $0.12
    15 Jul 2024 $0.13 $0.00 0.00% 524,413 $0.13 $0.14 $0.13
    12 Jul 2024 $0.13 $0.01 8.00% 3,255,204 $0.13 $0.13 $0.12
    11 Jul 2024 $0.13 $0.00 0.00% 360,963 $0.13 $0.13 $0.13
    10 Jul 2024 $0.13 $0.01 8.33% 2,028,390 $0.13 $0.13 $0.12
    09 Jul 2024 $0.12 $-0.01 -8.00% 5,016,547 $0.13 $0.13 $0.12
    08 Jul 2024 $0.13 $-0.01 -7.69% 3,753,788 $0.13 $0.13 $0.13
    05 Jul 2024 $0.13 $0.00 0.00% 137,767 $0.14 $0.14 $0.13
    04 Jul 2024 $0.13 $0.01 8.33% 2,394,685 $0.13 $0.14 $0.12
    03 Jul 2024 $0.12 $0.00 0.00% 937,573 $0.12 $0.12 $0.12
    02 Jul 2024 $0.12 $0.00 0.00% 2,273,390 $0.13 $0.13 $0.12
    01 Jul 2024 $0.12 $0.00 0.00% 2,053,756 $0.13 $0.13 $0.12
    28 Jun 2024 $0.12 $0.00 0.00% 1,515,830 $0.13 $0.13 $0.12
    27 Jun 2024 $0.12 $-0.01 -8.00% 901,253 $0.12 $0.13 $0.12
    26 Jun 2024 $0.13 $0.01 8.33% 1,189,354 $0.13 $0.13 $0.12
    25 Jun 2024 $0.12 $0.00 0.00% 2,973,004 $0.12 $0.13 $0.12
    24 Jun 2024 $0.12 $-0.02 -14.81% 5,132,936 $0.14 $0.14 $0.12
    21 Jun 2024 $0.14 $0.00 0.00% 7,025,733 $0.14 $0.14 $0.13
    20 Jun 2024 $0.14 $0.02 17.39% 19,060,081 $0.13 $0.14 $0.13
    19 Jun 2024 $0.12 $0.01 9.52% 7,975,384 $0.11 $0.12 $0.11
    18 Jun 2024 $0.11 $-0.01 -9.09% 1,625,311 $0.11 $0.11 $0.11

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    17 May 2024 Alan Tribe Buy 50,000,000 $5,250,000
    Off-market trade.
    26 Mar 2024 Alan Tribe Issued 307,453,493 $24,596,279
    Rights issue.
    03 Jan 2024 Rohan Hockings Transfer 18,181,818 $1,818,181
    Off-market transfer.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Alan William Tribe Non-Executive ChairmanNon-Executive Director Apr 2018
    Mr Tribe has a background in the accounting profession both in the UK and Australia. Moving into industry he became the Managing Director of a group of companies with interests in natural resources in Australia and overseas. The group also included a technology Group which grew through both successful product development and acquisitions. He was closely involved in establishing subsidiary operations in the USA, UK and Singapore to access markets worldwide. Most recently he was the catalyst for the development of large retail operations in Western and South Australia. Mr Tribe will contribute his experience in successfully commercialising technology internationally.
    Dr Rohan Hockings Executive DirectorChief Executive Officer Aug 2016
    Dr Hockings spent four years with McKinsey & Company and a further two years in the Private Equity industry before joining PYC Therapeutics. He brings an affinity for conceptual thinking to PYC Therapeutics along with an understanding of the company's technology and its commercialisation path. Dr Hockings is a founding principal of a private equity fund active in the acquisition of health care assets within Australia. His previous roles include strategy and operational advisory positions with a global management consulting firm, equity capital markets experience as a solicitor with a national law firm and a number of appointments as a medical practitioner. Dr Hockings has a special interest in both venture capital and private equity within the healthcare industry. Dr Hockings holds double degrees in medicine and law. He has worked across both disciplines following an internship at Sir Charles Gairdner Hospital and admission to practice in the Supreme Court of Victoria respectively.
    Dr Michael Rosenblatt Non-Executive Director Mar 2021
    Dr Rosenblatt is currently a Senior Partner of Flagship Pioneering. Dr Rosenblatt joined Flagship from Merck, where he served as Executive Vice President and Chief Medical Officer from 2009 to 2016. During an earlier period at Merck, he led drug discovery efforts in ophthalmology, molecular biology, bone biology, virology, cancer research, gastroenterology, lipid metabolism and cardiovascular research. He has held appointments as Dean of Tufts University School of Medicine; Robert H. Ebert Professor of Molecular Medicine and George R. Minot Professor of Medicine, both at Harvard Medical School; President, Harvard Faculty Dean and Senior Vice President for Academic Programs of Beth Israel Deaconess Medical Center; and Director of the Harvard-MIT Division of Health Sciences and Technology. Dr Rosenblatt has served as a founding scientist, scientific advisory board member or director of more than 12 biopharmaceutical companies. He completed internship, residency and endocrinology training at the Massachusetts General Hospital.
    Mr Jason Haddock Non-Executive Director Mar 2021
    Mr Haddock has more than 20 years of financial and operational experience in the biopharmaceutical industry and currently serves as a Board Director of Codiak Biosciences, a biotech company developing precision exosome therapeutics. He served as CFO at Array BioPharma, Inc., where he was instrumental in the execution of an oncology-focused research, development and commercialization strategy that culminated in the successful launch of two new drugs and the company ultimately being acquired by Pfizer. Prior, he worked at Bristol-Myers Squibb in a variety of finance, strategic, commercial and business development capacities, including CFO and COO roles for business units in Asia Pacific, Europe and the United States. Mr. Haddock has also served as CFO for ArcherDX as the company was acquired by Invitae to create a global leader in comprehensive cancer genetics and precision oncology.
    Mr Kevin R Hart Chief Financial OfficerCompany Secretary Jul 2017
    Mr Andrew Taylor Company Secretary Jun 2023
    Kevin R Hart Chief Financial OfficerCompany Secretary
    Andrew Taylor Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    No information of Shareholder 0 0.00%